-
Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic target. Proc Natl Acad Sci U S A. 2025 Nov 18; 122(46):e2513468122. Zhang X, Yang Y, Zou H, Cai D, Corey E, Zoubeidi A, Lo SH, Yu AM, Evans RM, Chen HW. PMID: 41231955; PMCID: PMC12646269.
-
Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors. Acta Pharm Sin B. 2025 Mar; 15(3):1415-1429. Zhang X, Yang Y, Zou H, Yang Y, Zheng X, Corey E, Zoubeidi A, Mitsiades N, Yu AM, Li Y, Chen HW. PMID: 40370549; PMCID: PMC12069891.
-
In Vivo Fermentation Production of RNA Interference Agents. Methods Mol Biol. 2025; 2965:489-500. Batra N, Tu MJ, Yu AM. PMID: 40877523; PMCID: PMC12888826.
-
PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells. Cancer Res Commun. 2024 11 01; 4(11):2976-2985. Schaaf ZA, Ning S, Leslie AR, Sharifi M, Gao RY, Maine JP, Lou W, Lombard AP, Liu C, Yu AM, Mitsiades N, Gao AC. PMID: 39440945; PMCID: PMC11577557.
-
The Growing Class of Novel RNAi Therapeutics. Mol Pharmacol. 2024 Jun 18; 106(1):13-20. Traber GM, Yu AM. PMID: 38719476; PMCID: PMC11187687.
-
Novel RNA molecular bioengineering technology efficiently produces functional miRNA agents. RNA. 2024 05 16; 30(6):680-694. Traber GM, Yi C, Batra N, Tu MJ, Yu AM. PMID: 38429100; PMCID: PMC11098458.
-
Molecular Engineering of Functional SiRNA Agents. ACS Synth Biol. 2024 06 21; 13(6):1906-1915. Batra N, Tu MJ, Yu AM. PMID: 38733599; PMCID: PMC11197084.
-
Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research. Drug Metab Dispos. 2023 06; 51(6):685-699. Cronin JM, Yu AM. PMID: 36948592; PMCID: PMC10197202.
-
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies. J Pharmacol Exp Ther. 2023 01; 384(1):133-154. Traber GM, Yu AM. PMID: 35680378; PMCID: PMC9827509.
-
Bioengineered RNA Therapy in Patient-Derived Organoids and Xenograft Mouse Models. Methods Mol Biol. 2022; 2521:191-206. Tu MJ, Yi CM, Traber GM, Yu AM. PMID: 35732999; PMCID: PMC9484490.
-
Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo. Acta Pharm Sin B. 2021 Dec; 11(12):3950-3965. Deng L, Petrek H, Tu MJ, Batra N, Yu AX, Yu AM. PMID: 35024318; PMCID: PMC8727917.
-
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. Pharmacol Ther. 2022 02; 230:107967. Yu AM, Tu MJ. PMID: 34403681; PMCID: PMC9477512.
-
RNA therapeutics: From biochemical pharmacology to technology development and clinical applications. Biochem Pharmacol. 2021 07; 189:114567. Ning B, Yu AM. PMID: 33865832; PMCID: PMC9514225.
-
Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling. Cancers (Basel). 2021 Apr 01; 13(7). Zhang X, Huang Z, Wang J, Ma Z, Yang J, Corey E, Evans CP, Yu AM, Chen HW. PMID: 33916325; PMCID: PMC8036795.
-
A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism. J Pharmacol Exp Ther. 2021 Jun; 377(3):305-315. Choi YH, Zhang C, Liu Z, Tu MJ, Yu AX, Yu AM. PMID: 33712506; PMCID: PMC8140393.
-
In vivo fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy. Theranostics. 2021; 11(10):4858-4871. Li PC, Tu MJ, Ho PY, Batra N, Tran MML, Qiu JX, Wun T, Lara PN, Hu X, Yu AX, Yu AM. PMID: 33754032; PMCID: PMC7978307.
-
Single bioengineered ncRNA molecule for dual-targeting toward the control of non-small cell lung cancer patient-derived xenograft tumor growth. Biochem Pharmacol. 2021 07; 189:114392. Petrek H, Yan Ho P, Batra N, Tu MJ, Zhang Q, Qiu JX, Yu AM. PMID: 33359565; PMCID: PMC8187260.
-
Expression and Purification of tRNA/ pre-miRNA-Based Recombinant Noncoding RNAs. Methods Mol Biol. 2021; 2323:249-265. Tu MJ, Wright HK, Batra N, Yu AM. PMID: 34086286; PMCID: PMC9516694.
-
Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. Drug Metab Dispos. 2020 12; 48(12):1257-1263. Jilek JL, Tu MJ, Zhang C, Yu AM. PMID: 33051247; PMCID: PMC7684025.
-
MicroRNA-1291-5p Sensitizes Pancreatic Carcinoma Cells to Arginine Deprivation and Chemotherapy through the Regulation of Arginolysis and Glycolysis. Mol Pharmacol. 2020 12; 98(6):686-694. Tu MJ, Duan Z, Liu Z, Zhang C, Bold RJ, Gonzalez FJ, Kim EJ, Yu AM. PMID: 33051382; PMCID: PMC7673485.
-
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges. Pharmacol Rev. 2020 10; 72(4):862-898. Yu AM, Choi YH, Tu MJ. PMID: 32929000; PMCID: PMC7495341.
-
The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19). Int J Mol Sci. 2020 Sep 03; 21(17). Batra N, De Souza C, Batra J, Raetz AG, Yu AM. PMID: 32899231; PMCID: PMC7503392.
-
Pharmacokinetic Analysis of Huangqi Guizhi Wuwu Decoction on Blood and Brain Tissue in Rats with Normal and Cerebral Ischemia-Reperfusion Injury by Microdialysis with HPLC-MS/MS. Drug Des Devel Ther. 2020; 14:2877-2888. Zheng HZ, Shen X, He YY, Yan XL, Wang SX, Yu AM, Wang LS. PMID: 32764886; PMCID: PMC7382588.
-
A novel miR-1291-ERRα-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis. Theranostics. 2020; 10(16):7193-7210. Chen Y, Zhou Y, Han F, Zhao Y, Tu M, Wang Y, Huang C, Fan S, Chen P, Yao X, Guan L, Yu AM, Gonzalez FJ, Huang M, Bi H. PMID: 32641987; PMCID: PMC7330864.
-
The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug. Front Oncol. 2020; 10:222. Li DF, Yuan Y, Tu MJ, Hu X, Li YZ, Yi WR, Li PC, Zhao Y, Cheng Z, Yu AM, Jian C, Yu AX. PMID: 32161722; PMCID: PMC7052494.
-
Novel approaches for efficient in vivo fermentation production of noncoding RNAs. Appl Microbiol Biotechnol. 2020 Mar; 104(5):1927-1937. Yu AM, Batra N, Tu MJ, Sweeney C. PMID: 31953559; PMCID: PMC7385725.
-
MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential. Pharmacol Res Perspect. 2019 12; 7(6):e00528. Petrek H, Yu AM. PMID: 31859460; PMCID: PMC6923806.
-
Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics. Acta Pharm Sin B. 2020 Jan; 10(1):159-170. Yi W, Tu MJ, Liu Z, Zhang C, Batra N, Yu AX, Yu AM. PMID: 31993313; PMCID: PMC6976971.
-
A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells. Cancer Res. 2020 02 01; 80(3):418-429. Umeh-Garcia M, Simion C, Ho PY, Batra N, Berg AL, Carraway KL, Yu A, Sweeney C. PMID: 31694904; PMCID: PMC7002233.
-
Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B. 2019 Nov; 9(6):1113-1144. Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, Wang X, Lyu Y, Chen X, Liu K, Yu AM, Zuo Z, Bi H. PMID: 31867160; PMCID: PMC6900561.
-
Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics. Biochem Pharmacol. 2019 11; 169:113638. Ning B, Yu D, Yu AM. PMID: 31518552; PMCID: PMC6802278.
-
Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs. Appl Microbiol Biotechnol. 2019 Aug; 103(15):6107-6117. Petrek H, Batra N, Ho PY, Tu MJ, Yu AM. PMID: 31187211; PMCID: PMC7068804.
-
A reliable LC-MS/MS method for the quantification of natural amino acids in mouse plasma: Method validation and application to a study on amino acid dynamics during hepatocellular carcinoma progression. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 15; 1124:72-81. Liu Z, Tu MJ, Zhang C, Jilek JL, Zhang QY, Yu AM. PMID: 31177050; PMCID: PMC6626562.
-
Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. Biomaterials. 2019 07; 210:25-40. Xu J, Sun J, Ho PY, Luo Z, Ma W, Zhao W, Rathod SB, Fernandez CA, Venkataramanan R, Xie W, Yu AM, Li S. PMID: 31054369; PMCID: PMC6538300.
-
Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. Transl Oncol. 2019 Apr; 12(4):683-692. Duan Z, Chinn D, Tu MJ, Zhang QY, Huynh J, Chen J, Mack P, Yu AM, Kim EJ. PMID: 30844579; PMCID: PMC6402293.
-
Bioengineered Let-7c Inhibits Orthotopic Hepatocellular Carcinoma and Improves Overall Survival with Minimal Immunogenicity. Mol Ther Nucleic Acids. 2019 Mar 01; 14:498-508. Jilek JL, Zhang QY, Tu MJ, Ho PY, Duan Z, Qiu JX, Yu AM. PMID: 30753993; PMCID: PMC6370598.
-
A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma. PLoS One. 2018; 13(12):e0209941. Alegre F, Ormonde AR, Snider KM, Woolard K, Yu AM, Wittenburg LA. PMID: 30596759; PMCID: PMC6312226.
-
Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression. Acta Pharm Sin B. 2019 May; 9(3):639-647. Li X, Tian Y, Tu MJ, Ho PY, Batra N, Yu AM. PMID: 31193825; PMCID: PMC6543075.
-
RNA therapy: Are we using the right molecules? Pharmacol Ther. 2019 04; 196:91-104. Yu AM, Jian C, Yu AH, Tu MJ. PMID: 30521885; PMCID: PMC6450780.
-
Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. Cancer Lett. 2019 02 01; 442:82-90. Tu MJ, Ho PY, Zhang QY, Jian C, Qiu JX, Kim EJ, Bold RJ, Gonzalez FJ, Bi H, Yu AM. PMID: 30389433; PMCID: PMC6311422.
-
Effects of carnitine palmitoyltransferases on cancer cellular senescence. J Cell Physiol. 2019 02; 234(2):1707-1719. Guan L, Chen Y, Wang Y, Zhang H, Fan S, Gao Y, Jiao T, Fu K, Sun J, Yu A, Huang M, Bi H. PMID: 30070697.
-
Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo. Int J Pharm. 2018 Aug 25; 547(1-2):537-544. Zhang QY, Ho PY, Tu MJ, Jilek JL, Chen QX, Zeng S, Yu AM. PMID: 29894758; PMCID: PMC6388695.
-
Carnitine palmitoyltransferase 1C regulates cancer cell senescence through mitochondria-associated metabolic reprograming. Cell Death Differ. 2018 03; 25(4):735-748. Wang Y, Chen Y, Guan L, Zhang H, Huang Y, Johnson CH, Wu Z, Gonzalez FJ, Yu A, Huang P, Wang Y, Yang S, Chen P, Fan X, Huang M, Bi H. PMID: 29317762; PMCID: PMC5864250.
-
Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells. Drug Metab Dispos. 2018 01; 46(1):2-10. Li PC, Tu MJ, Ho PY, Jilek JL, Duan Z, Zhang QY, Yu AX, Yu AM. PMID: 29061583; PMCID: PMC5733456.
-
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget. 2017 May 09; 8(19):30742-30755. Jian C, Tu MJ, Ho PY, Duan Z, Zhang Q, Qiu JX, DeVere White RW, Wun T, Lara PN, Lam KS, Yu AX, Yu AM. PMID: 28415566; PMCID: PMC5458164.
-
Comparing early liver graft function from heart beating and living-donors: A pilot study aiming to identify new biomarkers of liver injury. Biopharm Drug Dispos. 2017 Jul; 38(5):326-339. Yang QJ, Kluger M, Gorynski K, Pawliszyn J, Bojko B, Yu AM, Noh K, Selzner M, Jerath A, McCluskey S, Pang KS, Wasowicz M. PMID: 28102538.
-
PPARα regulates tumor cell proliferation and senescence via a novel target gene carnitine palmitoyltransferase 1C. Carcinogenesis. 2017 04 01; 38(4):474-483. Chen Y, Wang Y, Huang Y, Zeng H, Hu B, Guan L, Zhang H, Yu AM, Johnson CH, Gonzalez FJ, Huang M, Bi H. PMID: 28334197; PMCID: PMC6248526.
-
Effects of MicroRNA-34a on the Pharmacokinetics of Cytochrome P450 Probe Drugs in Mice. Drug Metab Dispos. 2017 05; 45(5):512-522. Jilek JL, Tian Y, Yu AM. PMID: 28254952; PMCID: PMC5399649.
-
Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharm Sin B. 2017 03; 7(2):241-248. Yu AM, Ingelman-Sundberg M, Cherrington NJ, Aleksunes LM, Zanger UM, Xie W, Jeong H, Morgan ET, Turnbaugh PJ, Klaassen CD, Bhatt AP, Redinbo MR, Hao P, Waxman DJ, Wang L, Zhong XB. PMID: 28388695; PMCID: PMC5343155.
-
Down-regulation of the placental BCRP/ABCG2 transporter in response to hypoxia signaling. Placenta. 2017 03; 51:57-63. Francois LN, Gorczyca L, Du J, Bircsak KM, Yen E, Wen X, Tu MJ, Yu AM, Illsley NP, Zamudio S, Aleksunes LM. PMID: 28292469; PMCID: PMC5354084.
-
Lyme disease spirochaete Borrelia burgdorferi does not require thiamin. Nat Microbiol. 2016 Nov 21; 2:16213. Zhang K, Bian J, Deng Y, Smith A, Nunez RE, Li MB, Pal U, Yu AM, Qiu W, Ealick SE, Li C. PMID: 27869793; PMCID: PMC5157048.
-
Advanced knowledge in drug metabolism and pharmacokinetics. Acta Pharm Sin B. 2016 Sep; 6(5):361-362. Yu AM, Zhong XB. PMID: 27709004; PMCID: PMC5045544.
-
Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells. Eur J Pharm Sci. 2016 Oct 10; 93:431-6. Rodrigues AC, Neri EA, Veríssimo-Filho S, Rebouças NA, Hirata RD, Yu AM. PMID: 27575876; PMCID: PMC5851013.
-
Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. Acta Pharm Sin B. 2016 Sep; 6(5):492-503. Jiang XL, Shen HW, Mager DE, Schmidt S, Yu AM. PMID: 27709018; PMCID: PMC5045556.
-
MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. Oncotarget. 2016 Jul 19; 7(29):45547-45561. Tu MJ, Pan YZ, Qiu JX, Kim EJ, Yu AM. PMID: 27322206; PMCID: PMC5216741.
-
Bioengineered non-coding RNA agent (BERA) in action. Bioengineered. 2016 Nov; 7(6):411-417. Duan Z, Yu AM. PMID: 27415469; PMCID: PMC5094625.
-
Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest. Sci Rep. 2016 05 24; 6:26611. Zhao Y, Tu MJ, Wang WP, Qiu JX, Yu AX, Yu AM. PMID: 27216562; PMCID: PMC4877571.
-
Metabolomics reveals mycoplasma contamination interferes with the metabolism of PANC-1 cells. Anal Bioanal Chem. 2016 Jun; 408(16):4267-73. Yu T, Wang Y, Zhang H, Johnson CH, Jiang Y, Li X, Wu Z, Liu T, Krausz KW, Yu A, Gonzalez FJ, Huang M, Bi H. PMID: 27074779; PMCID: PMC6300981.
-
Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms. Pharmacol Rep. 2016 Jun; 68(3):608-15. Jiang XL, Shen HW, Yu AM. PMID: 26977821; PMCID: PMC4848137.
-
Bioengineering of noncoding RNAs for research agents and therapeutics. Wiley Interdiscip Rev RNA. 2016 Mar-Apr; 7(2):186-97. Ho PY, Yu AM. PMID: 26763749; PMCID: PMC4769674.
-
MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy. Drug Metab Dispos. 2016 Mar; 44(3):308-19. Yu AM, Tian Y, Tu MJ, Ho PY, Jilek JL. PMID: 26566807; PMCID: PMC4767381.
-
Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth. Biochem Pharmacol. 2015 Dec 15; 98(4):602-13. Zhao Y, Tu MJ, Yu YF, Wang WP, Chen QX, Qiu JX, Yu AX, Yu AM. PMID: 26518752; PMCID: PMC4725324.
-
Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization. J Pharmacol Exp Ther. 2015 Aug; 354(2):131-41. Wang WP, Ho PY, Chen QX, Addepalli B, Limbach PA, Li MM, Wu WJ, Jilek JL, Qiu JX, Zhang HJ, Li T, Wun T, White RD, Lam KS, Yu AM. PMID: 26022002; PMCID: PMC4518075.
-
Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity. Drug Metab Dispos. 2015 Jul; 43(7):1129-36. Li MM, Addepalli B, Tu MJ, Chen QX, Wang WP, Limbach PA, LaSalle JM, Zeng S, Huang M, Yu AM. PMID: 25934574; PMCID: PMC4468437.
-
A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res. 2015 Apr 20; 43(7):3857-69. Chen QX, Wang WP, Zeng S, Urayama S, Yu AM. PMID: 25800741; PMCID: PMC4402540.
-
Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors. Neuropharmacology. 2015 Feb; 89:342-51. Jiang XL, Shen HW, Yu AM. PMID: 25446678; PMCID: PMC4310233.
-
Effects of nicotinamide N-methyltransferase on PANC-1 cells proliferation, metastatic potential and survival under metabolic stress. Cell Physiol Biochem. 2015; 35(2):710-21. Yu T, Wang YT, Chen P, Li YH, Chen YX, Zeng H, Yu AM, Huang M, Bi HC. PMID: 25592232.
-
Interplay of Breast Cancer Resistance Protein (BCRP) and Metabolizing Enzymes. Curr Drug Metab. 2015; 16(10):877-93. Tian Y, Bian Y, Jiang Y, Qian S, Yu A, Zeng S. PMID: 26652256.
-
Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos. 2014 Nov; 42(11):1791-5. Li MM, Wang WP, Wu WJ, Huang M, Yu AM. PMID: 25161167; PMCID: PMC4201134.
-
N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. Carcinogenesis. 2014 Oct; 35(10):2264-72. Bi HC, Pan YZ, Qiu JX, Krausz KW, Li F, Johnson CH, Jiang CT, Gonzalez FJ, Yu AM. PMID: 25115443; PMCID: PMC4178474.
-
FOXO1-dependent DNA damage repair is regulated by JNK in lung cancer cells. Int J Oncol. 2014 Apr; 44(4):1284-92. Ju Y, Xu T, Zhang H, Yu A. PMID: 24452601.
-
ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des. 2014; 20(5):793-807. Choi YH, Yu AM. PMID: 23688078; PMCID: PMC6341993.
-
Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice. J Biol Chem. 2014 Feb 07; 289(6):3105-13. Koh KH, Pan X, Shen HW, Arnold SL, Yu AM, Gonzalez FJ, Isoherranen N, Jeong H. PMID: 24318876; PMCID: PMC3916516.
-
Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. Drug Metab Dispos. 2013 Oct; 41(10):1725-31. Ingelman-Sundberg M, Zhong XB, Hankinson O, Beedanagari S, Yu AM, Peng L, Osawa Y. PMID: 23918665; PMCID: PMC3781370.
-
Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos. 2013 Oct; 41(10):1744-51. Pan YZ, Zhou A, Hu Z, Yu AM. PMID: 23686318; PMCID: PMC3781368.
-
Potential role of CYP2D6 in the central nervous system. Xenobiotica. 2013 Nov; 43(11):973-84. Cheng J, Zhen Y, Miksys S, Beyoglu D, Krausz KW, Tyndale RF, Yu A, Idle JR, Gonzalez FJ. PMID: 23614566; PMCID: PMC3750078.
-
Study of the response regulator Rrp1 reveals its regulatory role in chitobiose utilization and virulence of Borrelia burgdorferi. Infect Immun. 2013 May; 81(5):1775-87. Sze CW, Smith A, Choi YH, Yang X, Pal U, Yu A, Li C. PMID: 23478317; PMCID: PMC3647990.
-
Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status. Drug Metab Dispos. 2013 May; 41(5):975-86. Jiang XL, Shen HW, Mager DE, Yu AM. PMID: 23393220; PMCID: PMC3629804.
-
An overview of ABC and SLC drug transporter gene regulation. Curr Drug Metab. 2013 Feb; 14(2):253-64. Chen QX, Hu HH, Zhou Q, Yu AM, Zeng S. PMID: 23116109.
-
Noncoding microRNAs: small RNAs play a big role in regulation of ADME? Acta Pharm Sin B. 2012 Apr; 2(2):93-101. Yu AM, Pan YZ. PMID: 32154096; PMCID: PMC7061715.
-
miRdSNP: a database of disease-associated SNPs and microRNA target sites on 3'UTRs of human genes. BMC Genomics. 2012 Jan 25; 13:44. Bruno AE, Li L, Kalabus JL, Pan Y, Yu A, Hu Z. PMID: 22276777; PMCID: PMC3287127.
-
Humanized transgenic mouse models for drug metabolism and pharmacokinetic research. Curr Drug Metab. 2011 Dec; 12(10):997-1006. Shen HW, Jiang XL, Gonzalez FJ, Yu AM. PMID: 22023319; PMCID: PMC6310623.
-
MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines. Biopharm Drug Dispos. 2011 Sep; 32(6):355-67. Rodrigues AC, Li X, Radecki L, Pan YZ, Winter JC, Huang M, Yu AM. PMID: 21796641; PMCID: PMC3158292.
-
The riboswitch regulates a thiamine pyrophosphate ABC transporter of the oral spirochete Treponema denticola. J Bacteriol. 2011 Aug; 193(15):3912-22. Bian J, Shen H, Tu Y, Yu A, Li C. PMID: 21622748; PMCID: PMC3147507.
-
Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice. Pharmacol Biochem Behav. 2011 Sep; 99(3):311-5. Winter JC, Amorosi DJ, Rice KC, Cheng K, Yu AM. PMID: 21624387; PMCID: PMC3129464.
-
Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice. Drug Metab Dispos. 2011 Jul; 39(7):1227-34. Shen HW, Jiang XL, Yu AM. PMID: 21464174; PMCID: PMC3127237.
-
Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol. 2011 Mar 15; 81(6):783-92. Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, Yu AM. PMID: 21219875; PMCID: PMC3042498.
-
Altered cytochrome P450 expression in mice during pregnancy. Drug Metab Dispos. 2011 Feb; 39(2):165-9. Koh KH, Xie H, Yu AM, Jeong H. PMID: 20971892; PMCID: PMC3033691.
-
Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab. 2010 Oct; 11(8):659-66. Shen HW, Jiang XL, Winter JC, Yu AM. PMID: 20942780; PMCID: PMC3028383.
-
Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models. Drug Metab Rev. 2011 Feb; 43(1):27-40. Jiang XL, Gonzalez FJ, Yu AM. PMID: 20854191; PMCID: PMC3025535.
-
Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. Biochem Pharmacol. 2010 Jul 01; 80(1):122-8. Shen HW, Wu C, Jiang XL, Yu AM. PMID: 20206139; PMCID: PMC2879007.
-
Conference report: new analytical technologies for biological discovery. Bioanalysis. 2010 Feb; 2(2):181-4. Shen HW, Yu AM. PMID: 21083300.
-
Role of microRNAs in the regulation of drug metabolism and disposition. Expert Opin Drug Metab Toxicol. 2009 Dec; 5(12):1513-28. Yu AM. PMID: 19785514.
-
Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice. Drug Metab Lett. 2009 Dec; 3(4):234-41. Shen HW, Yu AM. PMID: 19995332; PMCID: PMC2879002.
-
MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos. 2009 Oct; 37(10):2112-7. Pan YZ, Gao W, Yu AM. PMID: 19581388; PMCID: PMC2769037.
-
Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. Biochem Pharmacol. 2009 Sep 15; 78(6):617-24. Wu C, Jiang XL, Shen HW, Yu AM. PMID: 19445902; PMCID: PMC2728464.
-
Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study. Bioanalysis. 2009 Apr; 1(1):87-95. Shen HW, Jiang XL, Yu AM. PMID: 20523750; PMCID: PMC2879651.
-
MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol. 2009 Jun; 75(6):1374-9. Pan YZ, Morris ME, Yu AM. PMID: 19270061; PMCID: PMC2684886.
-
Pinoline may be used as a probe for CYP2D6 activity. Drug Metab Dispos. 2009 Mar; 37(3):443-6. Jiang XL, Shen HW, Yu AM. PMID: 19095720; PMCID: PMC2680515.
-
Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymes. Drug Metab Dispos. 2009 Jan; 37(1):1-4. Zhang WY, Tu YB, Haining RL, Yu AM. PMID: 18838503; PMCID: PMC2683661.
-
Quantitation of human cytochrome P450 2D6 protein with immunoblot and mass spectrometry analysis. Drug Metab Dispos. 2009 Jan; 37(1):170-7. Yu AM, Qu J, Felmlee MA, Cao J, Jiang XL. PMID: 18832475; PMCID: PMC2683657.
-
Indolealkylamines: biotransformations and potential drug-drug interactions. AAPS J. 2008 Jun; 10(2):242-53. Yu AM. PMID: 18454322; PMCID: PMC2751378.
-
Aberrant expression of Kiss-1 and matrix metalloproteinase-9 are closely linked to lymph node metastasis of gastric cancer. Chin Med Sci J. 2008 Mar; 23(1):63-4. Zheng HC, Yu AM, Xin Y. PMID: 18437914.
-
Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos. 2008 Feb; 36(2):435-41. Felmlee MA, Lon HK, Gonzalez FJ, Yu AM. PMID: 18048490.
-
Small interfering RNA in drug metabolism and transport. Curr Drug Metab. 2007 Oct; 8(7):700-8. Yu AM. PMID: 17979658.
-
Expression, purification, and characterization of mouse CYP2d22. Drug Metab Dispos. 2006 Jul; 34(7):1167-74. Yu AM, Haining RL. PMID: 16595712.
-
Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol. 2006; 46:41-64. Gonzalez FJ, Yu AM. PMID: 16402898; PMCID: PMC1440291.
-
Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. J Pharmacol Exp Ther. 2006 Mar; 316(3):1328-34. Cheung C, Yu AM, Chen CS, Krausz KW, Byrd LG, Feigenbaum L, Edwards RJ, Waxman DJ, Gonzalez FJ. PMID: 16291874.
-
Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. J Lipid Res. 2006 Jan; 47(1):215-27. Inoue Y, Yu AM, Yim SH, Ma X, Krausz KW, Inoue J, Xiang CC, Brownstein MJ, Eggertsen G, Björkhem I, Gonzalez FJ. PMID: 16264197; PMCID: PMC1413576.
-
Potential role for human cytochrome P450 3A4 in estradiol homeostasis. Endocrinology. 2005 Jul; 146(7):2911-9. Yu AM, Fukamachi K, Krausz KW, Cheung C, Gonzalez FJ. PMID: 15817670.
-
The cyp2e1-humanized transgenic mouse: role of cyp2e1 in acetaminophen hepatotoxicity. Drug Metab Dispos. 2005 Mar; 33(3):449-57. Cheung C, Yu AM, Ward JM, Krausz KW, Akiyama TE, Feigenbaum L, Gonzalez FJ. PMID: 15576447.
-
Effects of protein kinase C on M-phase promoting factor in early development of fertilized mouse eggs. Cell Biochem Funct. 2004 Sep-Oct; 22(5):291-8. Yu BZ, Zheng J, Yu AM, Shi XY, Liu Y, Wu DD, Fu W, Yang J. PMID: 15338468.
-
Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev. 2004 May; 36(2):243-77. Yu AM, Idle JR, Gonzalez FJ. PMID: 15237854.
-
Hepatocyte nuclear factor 4alpha is a central regulator of bile acid conjugation. J Biol Chem. 2004 Jan 23; 279(4):2480-9. Inoue Y, Yu AM, Inoue J, Gonzalez FJ. PMID: 14583614.
-
Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics. 2003 Jun; 13(6):307-19. Yu AM, Idle JR, Herraiz T, Küpfer A, Gonzalez FJ. PMID: 12777961.
-
Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos. 2003 May; 31(5):548-58. Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, Krausz KW, Gonzalez FJ. PMID: 12695342.
-
Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther. 2003 Apr; 305(1):315-22. Yu AM, Idle JR, Krausz KW, Küpfer A, Gonzalez FJ. PMID: 12649384.
-
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics. 2003 Mar; 13(3):173-81. Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ. PMID: 12618595.
-
Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2. Carcinogenesis. 2003 Mar; 24(3):583-7. Kimura S, Kawabe M, Yu A, Morishima H, Fernandez-Salguero P, Hammons GJ, Ward JM, Kadlubar FF, Gonzalez FJ. PMID: 12663521.
-
The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine. J Pharmacol Exp Ther. 2003 Feb; 304(2):539-46. Yu AM, Granvil CP, Haining RL, Krausz KW, Corchero J, Küpfer A, Idle JR, Gonzalez FJ. PMID: 12538805.
-
Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther. 2002 Dec; 303(3):1291-300. Yu A, Kneller BM, Rettie AE, Haining RL. PMID: 12438554.
-
Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol. 2002 Jun 15; 63(12):2111-9. Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, Sellers EM. PMID: 12110370.
-
Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab Dispos. 2001 Nov; 29(11):1362-5. Yu A, Dong H, Lang D, Haining RL. PMID: 11602510.
-
Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 2001 Nov; 29(11):1514-20. Yu A, Haining RL. PMID: 11602530.
-
Purification, biochemical characterization and comparative enzyme kinetics of recombinant human CYP2D6 1 and CYP2D6 2 variants. Adv Exp Med Biol. 2001; 500:327-30. Yu A, Haining RL. PMID: 11764961.
US